Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07528274) titled 'Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure' on April 7.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Tianjin Medical University Cancer Institute and Hospital

Condition: NSCLC (Non-small Cell Lung Cancer) NSCLC (Advanced Non-small Cell Lung Cancer)

Intervention: Drug: Tislelizumab Drug: Docetaxel

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: May 1, 2026

Target Sample Size: 20

Countrie...